Company intelligence / Profile preview
KalGene Pharmaceuticals Inc.
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
Overview
KalGene is a Canadian biotech company developing precision medicine therapeutics. Its lead program KG207 is a bi-specific fusion protein designed to neutralize toxic beta amyloid oligomers implicated in Alzheimer’s disease. The company claims preclinical data show potential to slow or reverse progression with reduced risk of side effects compared to existing anti-Aβ monoclonal antibodies. Oncology programs have included antibody-based therapies and companion diagnostics for several solid tumors but are not the current primary focus.[1][2]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Monoclonal antibodiesBi-specific fusion proteinsCompanion diagnostics[1][2][3][4][9]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on KalGene Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KalGene Pharmaceuticals Inc..